Publicaciones (44) Publicaciones de María del Rosario Vidal Tocino

2024

  1. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  2. Cáncer de colon y recto

    Oncología clínica (Arán), pp. 303-317

  3. Cáncer gástrico, de páncreas y de las vías biliares

    Oncología clínica (Arán), pp. 273-289

  4. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry

    Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145

  5. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686

  6. Prevención del cáncer. Consejo genético y cáncer hereditario

    Oncología clínica (Arán), pp. 43-58

  7. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 864-871

  8. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2640-2651

  9. Use of multi-gene panels in patients at high risk of hereditary digestive cancer: position statement of AEG, SEOM, AEGH and IMPaCT-GENÓMICA consortium

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 3, pp. 293-318

2023

  1. Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival

    International Journal of Molecular Sciences, Vol. 24, Núm. 9

  2. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

  3. Telomere Length as a New Risk Marker of Early-Onset Colorectal Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

  4. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

2022

  1. Autoimmune Haemolytic Anaemia Due to Cold Antibodies in a Renal Cancer Patient

    Case Reports in Oncology, Vol. 15, Núm. 2, pp. 507-514

  2. Dysregulated Expression of Three Genes in Colorectal Cancer Stratifies Patients into Three Risk Groups

    Cancers, Vol. 14, Núm. 17

  3. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

  4. Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review

    Current Problems in Cancer: Case Reports, Vol. 6

  5. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy

    Frontiers in bioscience (Landmark edition), Vol. 27, Núm. 3, pp. 88

  6. Recurrent NOMO1 Gene Deletion Is a Potential Clinical Marker in Early-Onset Colorectal Cancer and Is Involved in the Regulation of Cell Migration

    Cancers, Vol. 14, Núm. 16

  7. Severe Hyponatremia Masking Central Diabetes Insipidus in a Patient with a Lung Adenocarcinoma

    Case Reports in Oncology, Vol. 15, Núm. 1, pp. 91-98